3-Hydroxyisobutyrate Dehydrogenase (HIBADH) deficiency - a novel disorder of valine metabolism by Meyer, Melanie et al.
OR I G I N A L AR T I C L E
3-Hydroxyisobutyrate dehydrogenase (HIBADH)
deficiency—A novel disorder of valine metabolism
Melanie Meyer1 | Jana C. Hollenbeck2 | Janine Reunert1 | Anja Seelhöfer1 |
Stephan Rust1 | Manfred Fobker3 | Saskia Biskup4 | Ulrike Och1 |
Mechthild Linden5 | Jörn Oliver Sass2 | Thorsten Marquardt1
1Department of General Pediatrics,
University Hospital, Münster, Germany
2Bonn-Rhein-Sieg University of Applied
Sciences, Department of Natural
Sciences & Institute for Functional Gene
Analytics (IFGA), RG Inborn Errors of
Metabolism, Rheinbach, Germany
3Center for Laboratory Medicine,
University Hospital, Münster, Germany






Children's Hospital Münster, Albert-
Schweitzer-Campus 1, Gebäude A13,
48149 Münster, Germany.
Email: marquat@uni-muenster.de
Communicating Editor: Pascale de
Lonlay
Abstract
3-Hydroxyisobutyric acid (3HiB) is an intermediate in the degradation of the
branched-chain amino acid valine. Disorders in valine degradation can lead to
3HiB accumulation and its excretion in the urine. This article describes the
first two patients with a new metabolic disorder, 3-hydroxyisobutyrate
dehydrogenase (HIBADH) deficiency, its phenotype and its treatment with a
low-valine diet. The detected mutation in the HIBADH gene leads to
nonsense-mediated mRNA decay of the mutant allele and to a complete loss-
of-function of the enzyme. Under strict adherence to a low-valine diet a rapid
decrease of 3HiB excretion in the urine was observed. Due to limited patient
numbers and intrafamilial differences in phenotype with one affected and one
unaffected individual, the clinical phenotype of HIBADH deficiency needs fur-
ther evaluation.
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1 | INTRODUCTION
Amino acids serve as basic components of protein bio-
synthesis, can act as neurotransmitters, or as starting
materials for hormone synthesis. Disorders of amino
acid degradation may lead to accumulation of poten-
tially toxic intermediates proximal to the metabolic
block and elevated concentrations in the plasma and
urine.
Valine is an essential branched-chain amino acid. It is
subject to a multistep degradation. A block in valine
degradation causes the accumulation of the intermedi-
ate 3-hydroxyisobutyric acid (3HiB) (see Figure 1) and
leads to 3-hydroxyisobutyrate aciduria (3HiBuria).
3HiBuria has been observed in different clinical condi-
tions1,2 (for a more detailed overview see the introduc-
tion of Sass et al3).
Mutations in the ALDH6A1 gene, coding for met-
hylmalonate semialdehyde dehydrogenase (MMSDH),3 lead
to accumulation of 3HiB and 3HiBuria. Loupatty et al4 have
suggested that mutations in HIBADH gene, coding for
3-hydroxyisobutyrate dehydrogenase (HIBADH) may also
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cause 3HiBuria, but until now, no patient with mutations
in this gene has been reported in the literature.
This article describes the first two patients with muta-
tions in the HIBADH gene leading to a complete loss-of-
function of its gene product. The index patient was evalu-
ated because of psychomotor retardation. A low-valine
diet decreased 3HiBuria and improved the clinical
condition.
2 | MATERIALS AND METHODS
Investigations and interventions were carried out after
informed consent of the patients and their parents. Data
analysis was approved by the local ethics committee
(Ethikkommission der Ärztekammer Westfalen-Lippe,
No. 2019-199-f-S).
2.1 | Gas chromatography-mass
spectrometry
Analysis of 3HiB in urine was performed by gas chro-
matography and mass spectrometry (GC/MS) as
described previously.5 Urine samples were normalized
to the same creatinine concentration. 3HiB values
were semiquantitated in relation to the internal stan-
dard phenylbutyric acid.
2.2 | DNA extraction
Genomic DNA was isolated from blood samples
according to the manufacturers' recommendations using
QIAamp DNA Blood Maxi Kit (Qiagen, Hilden, Ger-
many). DNA quantity and quality were determined using
both the Qubit Fluorometer and NanoDrop ND-8000
(Thermo Fisher Scientific, Dreieich, Germany).
2.3 | Genetic analysis
The coding and flanking intronic regions of the genes
HIBADH and ALDH6A1 were enriched using in solution
hybridization technology and were sequenced using the
Illumina HiSeq system. Copy number variations (CNV)
were computed on uniquely mapping, non-duplicate,
high quality reads using an internally developed method
based on sequencing coverage depth. CNV calling was
performed by computing the sample's normalized cover-
age profile and its deviation from the expected coverage.
Genomic regions are called as variant if they deviate sig-
nificantly from the expected coverage. Illumina
bcl2fastq2 was used to demultiplex sequencing reads.
Adapter removal was performed with the Skewer soft-
ware. The trimmed reads were mapped to the human ref-
erence genome (hg19) using the Burrows Wheeler
FIGURE 1 Multistep degradation of valine
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Aligner. Reads mapping to more than one location with
identical mapping score were discarded. Read duplicates
that likely result from PCR amplification were removed.
The remaining high quality sequences were used to
determine sequence variants (single nucleotide changes
and small insertions/deletions). Known disease-causing
variants (according to HGMD) were evaluated in up to
±30 bp of flanking regions and up to 5% minor allele fre-
quency (MAF). MAFs were taken from public databases
(eg, gnomAD browser) and an in-house database. In sil-
ico variant evaluation was carried out using the predic-
tion software MutationTaster6 and Provean,7 as well as
PolyPhen-2.8
2.4 | Gene expression analysis
The contribution of the c.582dupC; p.(Asn195Glnfs*25)
allele to total HIBADH mRNA in heterozygotes
was quantified by cDNA analysis. The genomic
sequence of exons 3-7 of the HIBADH gene in the het-
erozygous father of the patient was compared with the
corresponding sequence of the transcript at cDNA level.
RNA isolation was performed with the PAXgene Blood
RNA Kit (PreAnalytiX) from whole blood and cDNA
was synthesized from the isolated RNA using Super-
Script III Reverse Transcriptase (Invitrogen) according
to the manufacturer protocols. cDNA of the HIBADH
transcript of exons 3-7 was amplified by PCR. Primers
were styled with the open-source Primer3 software and
are available upon request. PCR products were purified
with the USB PCR Pre-Sequencing Kit (Affymetrix).
Sanger sequencing was done with BigDye Terminator
v3.1 (Applied Biosystems) according to the manufac-
turer's protocol.
2.5 | Biochemistry
Enzyme activity measurements in fibroblast homoge-
nates were performed as described,3 with the exception
that the Lowry test for protein quantitation was replaced
by the Bradford assay. Following protein separation by
SDS-PAGE, Western blot analyses of the homogenates
were done with a PVDF membrane (Bio RadL002045A)
and using the following antibodies: anti-HIBADH
(GeneTex GTX64844, LOT 821705878), 1:1500 in 5% skim
milk in Tris-buffered saline with Tween 20 (TBST) for
2 hours at room temperature (RT); anti-Rabbit IgG
(PE Health Care UKNA934V, LOT 13997044), 1:10 000 in
5% skim milk TBST 1:10 000 for 1 hour at RT; anti-alpha
tubulin (Abcam ab7291), 1:5 000 in 5% skim milk TBST
overnight at 4C; anti-mouse IgG linked with HRP
(PE Health Care NA931V, LOT 16953154), 1:10 000 in 5%
skim milk for 75 minutes at RT. TBST- Bands were
detected using the HRP-based West-Femto kit from
Thermo Fisher (#34095). Molecular weight standard was
Roti-Mark Western Plus (Carl Roth 2245.1, LOT
119281812).
2.6 | Therapy
The older patient was treated with a low-valine diet. This
diet was refused by the parents for the asymptomatic
younger sister who is also affected.
A protein-reduced diet was started with 0.8 g natural
protein/kg b.w. with addition of an isoleucine, leucine
and valine-free amino acid mixture (Milupa MSUD
2 PRIMA) and supplementation of isoleucine and leucine
according to WHO guidelines with 23 mg isoleucine and
44 mg leucine per kg b.w. (reference: WHO: Protein
and Amino Acid Requirements in Human Nutrition
2007, p. 180). In order to see whether an additional pro-
tein reduction would further decrease 3HiBuria, the sup-
ply of natural protein was stepwise decreased to a
minimum of 0.2 g/kg b.w. with a corresponding increase
of the valine-free amino acid mixture.
In order to avoid catabolism with endogenous valine
release from protein breakdown, sufficient calories were




The 11-year-old boy is the second child of a healthy con-
sanguineous couple of Syrian origin. He was born sponta-
neously in the 40th week of pregnancy. At the age of
7 months he was able to sit freely, he walked by himself
at 14 months and spoke his first two-word sentences at
the age of two. His further psychomotor development
was slower than in his siblings.
The boy shows hypomimia with an open mouth and
muscular hypotension. His movements are clumsy. The
gait pattern is wavering and shuffling with flapping
arms. Running is hardly possible, as the feet are only
slightly lifted from the ground. He shows a dystonic
position of both hands. During finger-tapping there is
mirror movement of the other hand and brady-
dysdiadochokinesia appears on both sides. Orders to fol-
low simple tasks have to be repeated and demonstrated
several times until they can be followed. His speech is
unclear and muffled.
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Examination of the cognitive development status at
the age of 6 years measured a SON-IQ of 63 in the
speech-free SON-R (Snijders-Oomen Non-verbal Intelli-
gence Test). This corresponded to a reference age of
4.6 years and was in the range of mental disability. A ren-
ewed examination of the cognitive development status at
the age of 8 years used the CFT 1-R (Culture Fair Intelli-
gence Test, Basic Intelligence Test Scale 1) and measured
a total IQ of 85 (percentile rank = 16). An additional test
at the age of 9 years confirmed the lower than average
total IQ. Apart from a small cyst of the pineal gland, the
cranial MRI showed no abnormalities.
Laboratory tests showed normal serum concentra-
tions of amino acids, lactate and ketone bodies. Urinary
organic acid analysis revealed a high excretion of 3HiB
(Figure 2).
His 3-year-old sister also showed elevated excretion of
3HiB in the urine. She was not formally tested but
reached developmental milestones within the normal
time frames. Unlike her brother, she shows no pheno-
typic abnormalities.
3.2 | Genetic analysis
No mutations in the ALDH6A1 gene were found. In the
HIBADH gene, the homozygous mutation c.582dupC p.
(Asn195Glnfs*25) in exon 5 was identified in both
siblings. This mutation leads to a frame shift and to the
formation of a premature stop-codon in exon 6. The par-
ents are heterozygous carriers and healthy.
3.3 | Gene expression analysis
In order to investigate a possible nonsense-mediated
RNA decay of the allele carrying the c.582dupC p.
(Asn195Glnfs*25) mutation, the alleles of the HIBADH
gene were sequenced at the genomic and at the cDNA
level in leukocytes of the patient's heterozygous father.
If the mRNA transcribed from the normal and mutant
alleles would be equally stable, almost identical
sequence patterns in the upper and lower panel of
Figure 3 should be seen. However, different quantitative
ratios in the cDNA vs genomic DNA of the bases to one
another at and downstream of the mutation site were
observed (Figure 3). To estimate the difference we
choose a position (green arrow Figure 3) where in the
genomic sequence the bases T and C (mutant allele)
have almost identical signal intensities (ie, 50:50, almost
perfect overlap of the signals), while in the cDNA there
is a ratio C/T of about 11.5:88.5. Based on these differ-
ences it was concluded that the majority of transcript of
the mutant allele (represented by the “C” at the green
arrow position) is degraded by nonsense-mediated
mRNA decay.
FIGURE 2 Organic acids in
urine of the index patient analyzed
by GC/MS. 3-Hydroxyisobutyric acid
at 11.61 minutes (blue arrow). IS
(internal standard): 3-Phenylbutyric
acid at 21.18 minutes
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3.4 | Enzyme activity
HIBADH enzymatic activity was determined in fibro-
blasts of patient 1 and of healthy controls (Table 1).
Residual activity in the patient was below the detection
level.
In Western blots, no HIBADH protein was detectable
in the patient cells (Figure 4).
FIGURE 3 Comparison of the sequences of the HIBADH gene at genomic level with the cDNA level in a heterozygote carrier of the
c.582dupC; p.(Asn195Glnfs*25) mutation. At the position of the green arrow the ratio of cytosine to thymine in the genomic sequence is
50:50. At the corresponding position in the cDNA of the HIBADH transcript, the ratio of cytosine to thymine is 11.5:88.5
TABLE 1 HIBADH enzyme activities: Mean ± SD
Patient Control 1 Control 2 Control 3
Enzyme activity μmol/(min*g) Not detectable (n = 5) 6.17 ± 2.87 (n = 5) 1.42 ± 0.90 (n = 4) 3.50 ± 0.93 (n = 5)
FIGURE 4 Western blot. 20 μg total protein
(determined with the Bradford method) were loaded
onto the SDS-PAGE gel. HIBADH (33 kDa) runs at
the position of the 30 kDa marker, the alpha tubulin
loading control at 50 kDa. Molecular weight standard
at the right side of the figure
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3.5 | Therapy
The low-valine diet was started at home (Figure 5). Insuf-
ficient adherence to dietary recommendations resulted in
2 periods of controlled dietary adherence in an inpatient
setting (Figure 5A,B) leading to a rapid decrease in 3HiB
excretion in the urine. 3HiB excretion did not reach nor-
mal levels, which was close to zero in healthy controls.
In the course of therapy, the parents reported an
improvement in language skills, as well as in the ability
to concentrate and in school performance. The parents
consider changing the school type from a special school
to a regular school.
4 | DISCUSSION
HIBADH deficiency due to mutations in HIBADH has
been suspected as a possible cause of 3HiBuria.2,4 Wan-
ders et al9 stated that they identified the first patient with
HIBADH deficiency, but did not provide further details
about genetic analysis or clinical phenotype. Mutations
in the ALDH6A1 gene and secondary causes which influ-
ence the presence or function of enzymes involved in
valine degradation—MMSDH and HIBADH—have been
published.
3HiBuria caused by homozygous missense mutations in
the ALDH6A1 gene was described by Chambliss et al and
Sass et al.3,10 Secondary inhibition of MMSDH due to an
increase of certain metabolites was described in glyoxylate
reductase/hydroxypyruvate reductase and AGXT2 enzyme
deficiency.11
HIBADH can be inhibited because of defects in the respi-
ratory chain and thus cause 3HiBuria. If the respiratory
chain is defective, a disturbed oxidation of NADH leads to an
increased NADH/NAD+-ratio.4 The increased NADH/
NAD+-ratio may cause an inhibition of HIBADH activity
(discussed in Sass et al3). This should be considered particu-
larly in case of increased lactate values in urine and plasma.
Heterogeneous symptoms have been described in
3HiBuria: Facial dysmorphisms such as a small triangu-
lar face, a long philtrum, small low-set ears,1 clinodactyly
of the toes,12 delayed psychomotor development,2 del-
ayed myelination and narrow corpus callosum as well as
intracranial calcification,13 eccentric hypertrophy of the
right ventricle and persistent pulmonary hypertension,4
seizures,1 fatal episodes of ketoacidosis.2 The range of
symptoms in 3HiBuria is wide and can extend from an
inconspicuous development14 to a severe developmental
disorder and also shows intrafamilial variability.13 Obvi-
ously, individuals with 3HiBuria represent a heteroge-
neous group with different underlying mechanisms.
The patient described here presented with psychomo-
tor retardation, low average total IQ values and a high
amount of 3HiB in urine. The already known causes of
3HiBuria could be excluded by an unobtrusive analysis
of the ALDH6A1 gene and normal lactate concentrations
in blood and urine. Expression analysis of HIBADH
showed degradation of the transcript of the mutated
allele by nonsense-mediated mRNA decay and a
FIGURE 5 Measurement of urinary 3HiB excretion with low valine diet. The 3HiB values in urine were determined by GC/MS and
presented in relation to a phenylbutyric acid standard. A, First and B, second inpatient stay
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complete loss of enzyme function. Altogether, our data
confirm that HIBADH deficiency is another cause for a
3HiBuria.
The 3-year-old sister of the index patient, who has the
same mutations and also has increased urinary excretion
of 3HiB, has reached all developmental milestones in
normal time frames. The intrafamilial variability—with
one phenotypically affected brother and one phenotypi-
cally unaffected sister—raises the possibility that
HIBADH deficiency is a biochemical alteration that may
not always cause symptoms. It cannot be excluded that
the phenotype of the index patient could be due to a sec-
ond, so far undiscovered disorder.
More patients with HIBADH deficiency have to be
found in order to fully evaluate the spectrum of clinical
symptoms and the value of valine restriction.
In conclusion, we report on the first patients with
3HiBuria caused by a homozygous loss-of-function muta-
tion in the HIBADH gene. Therapy with a low-valine diet
leads to a decrease of 3HiBuria. Our results expand the pre-
viously known causes of 3HiBuria by HIBADH deficiency.
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